参考文献
- Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth
factor receptor mutations in lung cancer. N Engl J Med, 2009, 361(10):
958-967.[LinkOut]
- Reply to Watkins and Rukazenkov ( J Cell Mol Med 2010), re-Letter of
response to manuscript entitled' clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010;
14(1-2): 51-69). J Cell Mol Med, 2011, 15(5):1225.[LinkOut]
- Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to
epidermal growth factor receptor antagonists in non-small-cell lung cancer. J
Clin Oncol, 2007, 25(5): 587-595.[LinkOut]
- T. Mitsudomi, Y. Yatabe. Mutations of the epidermal growth factor receptor
gene and related genes as determinants of epidermal growth factor receptor
tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science, 2007,
98(12): 1817-1824.[LinkOut]
- Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by
inhibitor-sensitive and -resistant EGFR mutants. PLoS Med, 2005, 2(11):
e313.[LinkOut]
- Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor
receptor and KRAS mutation patterns in non-small cell lung cancer patients
with different tobacco exposure and clinicopa-thologic features. Clin Cancer
Res, 2006, 12(5): 1647-1653.[LinkOut]
- Linardou H, Dahabreh IJ, Bafaloukos D, et al. Somatic EGFR mutations and
efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol, 2009,
6(6): 352-366.[LinkOut]
- Sun L, Zhang Q, Luan HL, et al. Comparison of KRAS and EGFR gene
status between primary non-small cell lung cancer and local lymph node
metastases: implications for clinical practice. J Experimental Clin Cancer
Res, 2011, 30(1): 30.[LinkOut]
- Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR
as biomarkers of response to erlotinib in National Cancer Institute of
Canada Clinical Trials Group Study BR.21. J Clin Oncol, 2008, 26(26):
4268-4275.[LinkOut]
- Sasaki H, Hikosaka Y, Kawano O, et al. Evaluation of Kras gene mutation
and copy number gain in non-small cell lung cancer. J Thorac Oncol, 2011,
6(1): 15-20.[LinkOut]
- Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF
dimers and ERK signalling in cells with wild-type BRAF. Nature, 2010,
464(7287): 427-430.[LinkOut]
- Pallis A, Briasoulis E, Linardou H, et al. Mechanisms of resistance to
epidermal growth factor receptor tyrosine kinase inhibitors in patients with
advanced non-small-cell lung cancer: clinical and molecular considerations.
Current Medicinal Chemistry, 2011, 18(11): 1613-1628.[LinkOut]
- Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome
of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin
Oncol, 2009, 27(26): 4247-4253.[LinkOut]
- Benedettini E, Sholl LM, Peyton M, et al. Met activation in non-small cell
lung cancer is associated with de novo resistance to EGFR inhibitors and the
development of brain metastasis. Am J Pathol, 2010, 177(1): 415-423.[LinkOut]
- Turke AB, Zejnullahu K, Wu YL, et al. Pre-existence and clonal selection
of MET amplification in EGFR mutant NSCLC. Cancer Cell, 2010, 17(1):
77-88.[LinkOut]
- Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance
to epidermal growth factor receptor tyrosine kinase inhibitors in non-smallcell
lung cancer. J Clin Oncol, 2010, 28(2): 357-360.[LinkOut]
- Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance
of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005, 352(8):
786-792.[LinkOut]
- Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR
kinase causes drug resistance by increasing the affinity for ATP. Proc Natl
Acad Sci USA, 2008, 105(6): 2070-2075.[LinkOut]
- Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor
receptor gene T790M mutation as a minor clone in non-small cell lung
cancer. Cancer Res, 2006, 66(16): 7854-7858.[LinkOut]
- Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR
in circulating lung-cancer cells. N Engl J Med, 2008, 359(4): 366-377.[LinkOut]
- Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to
gefitinib resistance in lung cancer by activating ERBB3 signaling. Science,
2007, 316(5827): 1039-1043.[LinkOut]
- Schiller JH, Akerley WL, Brugger W, et al. Results from ARQ 197-209: A
global randomized placebo-controlled phase II clinical trial of erlotinib plus
ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitornaive
patients with locally advanced or metastatic non-small cell lung cancer
(NSCLC). J Clin Oncol, 2010, 28: LBA7502.
- Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression
increases sensitivity to epidermal growth factor receptor inhibitors in lung
cancer cell lines. Cancer Res, 2006, 66(2): 944-950.[LinkOut]
- Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal
phenotype determines in vitro sensitivity and predicts clinical activity
of erlotinib in lung cancerpatients. Clin Cancer Res, 2005, 11(24 Pt1):
8686-8698.[LinkOut]
- Miyanaga A, Gemma A, Ando M, et al. E-cadherin expression and epidermal
growth factor receptor mutation status predict outcome in non-small
cell lung cancer patients treated with gefitinib. Oncol Rep, 2008,19(2):
377-383.[LinkOut]
- Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus
docetaxel in patients with non-small cell lung cancer harbouring mutations
of the epidermal growth factor receptor (WJTOG3405): an open label,
randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.[LinkOut]
- Morgillo F, Kim WY, Kim ES, et al. Implication of the insulin-like growth
factor-IR pathway in the resistance of non-small cell lung cancer cells to
treatment with gefitinib. Clin Cancer Res, 2007, 13(9): 2795-2803.[LinkOut]
- Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine
kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
J Clin Invest, 2008, 118(7): 2609-2619.[LinkOut]
- Ios ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib
resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
Cancer Res, 2009, 69(8): 3256-3261.[LinkOut]
- Kjm SM, Kim JS, Kim JH, et al. Acquired resistance to cetuximab is mediated
by increased PTEN instability and leads cross-resistance to gefitinib in
HCC827 NSCLC cells. Cancer Lett, 2010, 296(2): 150-159.[LinkOut]
- Vivanco I, Rohle D, Versele M, et al. The phosphatase and tensin homolog
regulates epidermal growth factor receptor (EGFR) inhibitor response by
targeting EGFR for degradation. Proc Natl Acad Sci USA, 2010, 107(14): 6459-6464.[LinkOut]
- Yao Z, Fenoglio S, Gao DC, et al. TGF-{beta} IL-6 axis mediates selective
and adaptive mechanisms of resistance to molecular targeted therapy in lung
cancer. Proc Natl Acad Sci USA, 2010, 107(35): 15535-15540.[LinkOut]
- Ware KE, Marshall ME, Heasley LR, et al. Rapidly acquired resistance to
EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression
of FGFR2 and FGFR3 expression. PLoS One, 2010, 5(11): e14117.[LinkOut]
- Chen YJ, Huang WC, Wei YL, et al. Elevated BCRP/ABCG2 expression
confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
PLoS One, 2011, 6(6): e21428.[LinkOut]
- Oxnard GR, Arcila ME, Chmielecki J, et al. New strategies in overcoming
acquired resistance to epidermal growth factor receptor tyrosine kinase
inhibitors in lung cancer. Clin Cancer Res, 2011, 17(17): 5530-5537.[LinkOut]
|